My bush man science understanding is that the 2RT is effective for a sub-set of patients with intermediate AMD (i.e. those who did not have coexistent reticular pseudodrusen (RPD)). It would be good to understand how much of the US$10bn market is now available to them and also the size of the VEGF market for patients not having RPD. The investor call tomorrow should be very informative.
Ann: ELX LEAD Clinical trial results, page-9
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $35.53M | |||
| Open | High | Low | Value | Volume |
| 14.0¢ | 14.0¢ | 13.5¢ | $55.53K | 409.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 793989 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 128738 | 2 |
View Market Depth
| Last trade - 15.43pm 11/02/2025 (20 minute delay) ? |
| EYE (ASX) Chart |